[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2014087367A3 - Compositions and methods for the treatment of neurological diseases and its associated complications - Google Patents

Compositions and methods for the treatment of neurological diseases and its associated complications Download PDF

Info

Publication number
WO2014087367A3
WO2014087367A3 PCT/IB2013/060667 IB2013060667W WO2014087367A3 WO 2014087367 A3 WO2014087367 A3 WO 2014087367A3 IB 2013060667 W IB2013060667 W IB 2013060667W WO 2014087367 A3 WO2014087367 A3 WO 2014087367A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compositions
disorders
methods
epilepsy
Prior art date
Application number
PCT/IB2013/060667
Other languages
French (fr)
Other versions
WO2014087367A2 (en
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/050740 external-priority patent/WO2013167986A2/en
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014087367A2 publication Critical patent/WO2014087367A2/en
Publication of WO2014087367A3 publication Critical patent/WO2014087367A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, seizures, mental diseases, mental disorders, schizophrenia, depression, bipolar disorder, Alzheimer's disease, anxiety, ADHD, dementia, mood disorders, PTSD, sleeplessness, epilepsy, migraine, psychosis, OCD, autism, anxiety disorders, dementia, mania and cognitive disorders.
PCT/IB2013/060667 2012-12-09 2013-12-05 Compositions and methods for the treatment of neurological diseases and its associated complications WO2014087367A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN5123CH2012 2012-12-09
IN5123/CHE/2012 2012-12-09
INPCT/IB2013/050740 2013-01-29
PCT/IB2013/050740 WO2013167986A2 (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy

Publications (2)

Publication Number Publication Date
WO2014087367A2 WO2014087367A2 (en) 2014-06-12
WO2014087367A3 true WO2014087367A3 (en) 2014-07-31

Family

ID=50884099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060667 WO2014087367A2 (en) 2012-12-09 2013-12-05 Compositions and methods for the treatment of neurological diseases and its associated complications

Country Status (1)

Country Link
WO (1) WO2014087367A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106511302B (en) * 2015-09-11 2020-06-05 重庆润泽医药有限公司 Levalsartan sustained-release capsule with good release uniformity and preparation method thereof
CN107510681B (en) * 2016-06-15 2020-07-03 重庆润泽医药有限公司 (S) -4-hydroxy-2 oxo-1-pyrrolidine acetamide particles and preparation method thereof
CN107510685B (en) * 2016-06-15 2020-07-21 重庆润泽医药有限公司 (S) -4-hydroxy-2-oxo-1-pyrrolidine acetamide particles with uniform content and preparation method thereof
CN106955274B (en) * 2016-07-13 2018-10-23 重庆润泽医药有限公司 - 2 oxo-1-pyrrolidine ethanamide spansule of one kind (S) -4- hydroxyls and preparation method thereof
CN107625751B (en) * 2016-07-14 2020-09-29 重庆润泽医药有限公司 Levo-oxiracetam sustained-release capsule with good stability and preparation method thereof
CN106955275B (en) * 2016-07-14 2018-10-26 重庆润泽医药有限公司 A kind of levo-oxiracetam spansule and preparation method thereof that stability is good
CN107661307A (en) * 2016-07-26 2018-02-06 重庆润泽医药有限公司 A kind of 2 oxo of (S) 4 hydroxyl 1 pyrrolidine acetamide spansule of high income and preparation method thereof
CN108567751A (en) * 2017-03-14 2018-09-25 重庆润泽医药有限公司 A kind of oxiracetam oral disintegrated preparation and preparation method thereof
CN108567749A (en) * 2017-03-14 2018-09-25 重庆润泽医药有限公司 A kind of levo-oxiracetam oral preparation of suitable children taking and preparation method thereof
CN109692166A (en) * 2017-10-23 2019-04-30 重庆润泽医药有限公司 The enteric slow release particle and preparation method thereof for treating epilepsy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145347A (en) * 1977-03-03 1979-03-20 Parke, Davis & Company N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides
WO2001062726A2 (en) * 2000-02-23 2001-08-30 Ucb, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
WO2008075366A2 (en) * 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
WO2010132693A2 (en) * 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing pyrrolidine compounds
WO2010144712A1 (en) * 2009-06-11 2010-12-16 Seradyn, Inc. Derivatives, reagents, and immunoassay for detecting levetiracetam
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145347A (en) * 1977-03-03 1979-03-20 Parke, Davis & Company N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidineacetamides
WO2001062726A2 (en) * 2000-02-23 2001-08-30 Ucb, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
WO2008075366A2 (en) * 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
WO2010132693A2 (en) * 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing pyrrolidine compounds
WO2010144712A1 (en) * 2009-06-11 2010-12-16 Seradyn, Inc. Derivatives, reagents, and immunoassay for detecting levetiracetam
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOYER M ET AL., EUR J PHARMACOL., vol. 286, no. 2, 14 November 1995 (1995-11-14), pages 137 - 146 *

Also Published As

Publication number Publication date
WO2014087367A2 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
WO2014087367A3 (en) Compositions and methods for the treatment of neurological diseases and its associated complications
CO6751271A2 (en) Imidazol [5,1-f] [1,2,4] triazines for the treatment of neurological disorders
JO3146B1 (en) Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders
RU2014145682A (en) ORGANIC COMPOUNDS
CL2015000096A1 (en) Compounds derived from 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta [a] naphthalenes, phosphodiestearase 2 and / or 10 inhibitors; pharmaceutical composition; and its use for prevention or treatment of diseases of the nervous system, such as cognitive deficiency, dementia, anxiety disorders, enf. from Alzheimer, enf. from parkinson, others
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX2015017169A (en) Heteroaromatic compounds and their use as dopamine d1 ligands.
AR079103A1 (en) MESILATE SALT COMPOSITE OF (S) -2- (4- (3-FLUORO-BENCILOXI) -BENCILAMINO) -PROPIONAMIDE, POLYMORPHIC FORM (NF6), PHARMACEUTICAL COMPOSITION, USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT AND ITS PROCESSES PREPARATION
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014057439A3 (en) Compositions and methods for treatment of neurological diseases and its associated complications
IN2014DN09826A (en)
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
NZ603967A (en) 8-hydroxy-quinoline derivatives
MX2014006015A (en) 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors.
EA201690971A1 (en) PYRIDO [4,3-b] PYRAZIN-2-CARBOXAMIDES AS NEUROGENOUS MEANS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
WO2013167986A3 (en) Compositions and methods for the treatment of epilepsy
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
NZ629855A (en) Sulphonamide derivatives of benzylamine for the treatment of cns diseases
WO2014060925A3 (en) Compositions and methods for treatment of neurological and neurodegenerative diseases
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014060941A3 (en) Compounds and compositions of neuroprotective agents for treatment of neurological and neurodegenerative diseases
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2014006528A3 (en) Compositions and methods for the treatment of neurological degenerative disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13861025

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13861025

Country of ref document: EP

Kind code of ref document: A2